adenosine A2B antagonists (Inspyr Therapeutics)

N/A

Report date: 2025/01/26 18:56:22
NME

Base Information

Drug Nameadenosine A2B antagonists (Inspyr Therapeutics)
Drug Alias Nameadenosine A2B antagonists (Lewis & Clark Pharmaceuticals)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAdenosine A2b receptor antagonists
TargetsAdenosine A2b receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2AtherosclerosisAsthma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesLewis & Clark Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesInspyr Therapeutics
Inactive CompaniesLewis & Clark Pharmaceuticals IncRidgeway Therapeutics Inc
Active IndicationsNeoplasms
Inactive IndicationsDiabetes Mellitus, Type 2AtherosclerosisAsthma

Other Information

ATC CodeN/A
Related LinksN/A